Drug Competition Enhancement Act

Hozzl · 2025-04-07T12:51:22Z

Explore the details of Senate Bill 1040 Drug Competition Enhancement Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

4/7/2025, 12:51 PM

Summary of Bill S 1040

Bill 119 s 1040, also known as the "Product Hopping Prohibition Act," aims to make changes to the Federal Trade Commission Act in order to prevent a practice known as product hopping. Product hopping occurs when a pharmaceutical company makes minor changes to a drug in order to extend its patent protection and prevent generic competition.

The bill seeks to prohibit this practice by requiring pharmaceutical companies to prove that any changes made to a drug are truly beneficial to patients and not just a way to stifle competition. This would help to ensure that consumers have access to more affordable generic versions of medications.

In addition to addressing product hopping, the bill also includes provisions for other purposes related to competition and consumer protection. These provisions are aimed at promoting fair competition in the pharmaceutical industry and protecting consumers from anti-competitive practices. Overall, Bill 119 s 1040 is designed to promote competition, lower drug prices, and protect consumers from unfair practices in the pharmaceutical industry. It is an important piece of legislation that aims to improve access to affordable medications for all Americans.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1040

Bill S 1040 is currently in the status of Bill Introduced since March 13, 2025. Bill S 1040 was introduced during Congress 119 and was introduced to the Senate on March 13, 2025. Bill S 1040's most recent activity was Committee on the Judiciary. Ordered to be reported without amendment favorably. as of April 3, 2025

Bipartisan Support of Bill S 1040

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1040

Primary Policy Focus

Health

Alternate Title(s) of Bill S 1040

A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.

Start holding our government accountable!